GlassScriptPhysician profile
Yen-Yi Peng
NPI 1891951638
$13,727.13
in general payments reported to CMS, 2019-2025
61 companies · $3,198 in 2025
The $3,198 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,476 · 2020: $887 · 2021: $1,124 · 2022: $1,662 · 2023: $2,738 · 2024: $2,642 · 2025: $3,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,566 · Education: $12.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,565.61 |
| Education | $12.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,526.65 | 2019-2025 | Briviact, Zilbrysq, Nayzilam |
| Abbvie INC. | $1,161.74 | 2019-2025 | |
| Neurocrine Biosciences, INC. | $1,020.40 | 2020-2025 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $768.35 | 2020-2025 | Xcopri |
| Biogen, INC. | $760.77 | 2020-2025 | Vumerity, Tysabri, Leqembi |
| Novartis Pharmaceuticals Corporation | $670.65 | 2019-2025 | |
| Emd Serono, INC. | $638.13 | 2019-2025 | Mavenclad |
| Pfizer INC. | $602.12 | 2019-2025 | |
| Mdd US Operations, LLC | $530.95 | 2019-2025 | Gocovri, Gocovri, Qelbree |
| Teva Pharmaceuticals USA, INC. | $525.52 | 2019-2025 | Austedo Xr, Austedo Xr |
| Genzyme Corporation | $505.06 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $396.66 | 2021-2024 | Rytary |
| Argenx US, INC. | $369.45 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Kyowa Kirin, INC. | $332.28 | 2020-2025 | Nourianz |
| Celgene Corporation | $285.76 | 2021-2024 | Zeposia |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $204.21 | 2019-2024 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $197.96 | 2023-2025 | Hyqvia |
| Janssen Pharmaceuticals, INC | $195.28 | 2021-2023 | Ponvory |
| Greenwich Biosciences, INC. | $189.29 | 2019-2021 | |
| Lundbeck LLC | $186.03 | 2020-2025 | Rexulti, Vyepti |
| Alexion Pharmaceuticals, INC. | $183.26 | 2019-2023 | Ultomiris |
| Sunovion Pharmaceuticals INC. | $167.70 | 2021-2022 | |
| Neurelis, INC. | $139.53 | 2023-2025 | Valtoco |
| Eisai INC. | $136.28 | 2019-2025 | |
| Aquestive Therapeutics, INC. | $136.09 | 2019-2021 | |
| Octapharma USA, INC. | $130.28 | 2021-2024 | Panzyga |
| Amgen INC. | $120.83 | 2024-2025 | Uplizna |
| Genentech USA, INC. | $110.31 | 2021-2025 | Ocrevus Zunovo, Ocrevus |
| Allergan, INC. | $108.48 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $108.20 | 2024-2025 | |
| Impel Pharmaceuticals INC. | $104.99 | 2022-2023 | Trudhesa |
| Otsuka America Pharmaceutical, INC. | $94.63 | 2023-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $85.98 | 2023-2025 | Kisunla, Zepbound, Amyvid |
| Csl Behring | $77.79 | 2021-2024 | Hizentra |
| Merz Pharmaceuticals, LLC | $74.44 | 2021-2025 | Xeomin, Ampyra, Inbrija |
| Sumitomo Pharma America, INC. | $69.94 | 2023-2024 | Aptiom |
| Ani Pharmaceuticals, INC. | $67.21 | 2023-2025 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $60.21 | 2022-2023 | Uplizna |
| Tanabe Pharma America, INC. | $56.06 | 2019-2023 | |
| Scilex Pharmaceuticals INC. | $55.67 | 2023-2024 | Ztlido |
| Acorda Therapeutics, INC | $43.76 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $42.30 | 2021 | |
| Grifols USA, LLC | $39.22 | 2024-2025 | Gamunex-C |
| Supernus Pharmaceuticals, INC. | $37.19 | 2019-2020 | |
| Ge Healthcare | $37.03 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $35.09 | 2023-2025 | Keveyis |
| Adamas Pharmaceuticals, INC. | $32.74 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $31.31 | 2024-2025 | |
| Boston Scientific Corporation | $31.26 | 2020-2021 | |
| Janssen Biotech, INC. | $28.15 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $27.16 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $26.26 | 2025 | Symbravo |
| Banner Life Sciences, LLC | $25.84 | 2022 | |
| Livanova USA, INC. | $22.49 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Cala Health, INC. | $19.78 | 2023 | Cala Kiq, Cala Trio |
| Avanir Pharmaceuticals, INC. | $18.51 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.67 | 2024 | Caplyta |
| Sanofi-Aventis U.S. LLC | $16.18 | 2020 | |
| Averitas Pharma INC. | $15.13 | 2023 | Qutenza |
| Zyla Life Sciences, INC. | $13.59 | 2020 | |
| Merz North America, INC. | $12.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yen-Yi Peng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.